Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Drug-Price Bill Pruned in Senate in Partial Industry Win (2)

Aug. 6, 2022, 5:39 PM

Medicare was cleared to negotiate drug prices for the first time by the Senate’s top rules official, though the Democrats’ proposal intended to cap price increases for prescription drugs in the commercial market was blocked.

A separate provision capping out-of-pocket costs for insulin at $35 per month for those with private insurance also was blocked, according to a person familiar with the matter. Democrats were still waiting for a decision on whether the limit could be applied under Medicare.

The rulings are a partial victory for drug makers, who could try to make up their lost profits in Medicare on ...